Insider Selling: CG Oncology (NASDAQ:CGON) Director Sells $350,000.00 in Stock

CG Oncology, Inc. (NASDAQ:CGON) Director Leonard Post sold 5,000 shares of the business’s stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $70.00, for a total transaction of $350,000.00. Following the sale, the director directly owned 5,000 shares in the company, valued at approximately $350,000. This represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

CG Oncology Stock Performance

Shares of CGON stock opened at $71.96 on Friday. The stock has a market cap of $6.35 billion, a PE ratio of -30.88 and a beta of 0.31. CG Oncology, Inc. has a 1 year low of $23.65 and a 1 year high of $75.50. The stock has a fifty day moving average price of $64.40 and a 200 day moving average price of $58.00.

CG Oncology (NASDAQ:CGON) last released its quarterly earnings results on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.13). The firm had revenue of $1.08 million during the quarter, compared to analyst estimates of $0.45 million. As a group, equities research analysts predict that CG Oncology, Inc. will post -2.89 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on CGON. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CG Oncology in a research note on Monday, April 20th. Royal Bank Of Canada upped their price objective on CG Oncology from $79.00 to $81.00 and gave the company an “outperform” rating in a research report on Monday, May 11th. Wedbush lifted their price objective on CG Oncology from $77.00 to $80.00 and gave the stock an “outperform” rating in a research report on Monday, May 11th. Wall Street Zen lowered shares of CG Oncology from a “hold” rating to a “sell” rating in a report on Saturday, April 25th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $100.00 price target on shares of CG Oncology in a research note on Monday, May 18th. Eleven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $81.73.

Institutional Investors Weigh In On CG Oncology

Institutional investors have recently added to or reduced their stakes in the company. NFSG Corp acquired a new position in shares of CG Oncology in the 1st quarter valued at about $34,000. Whittier Trust Co. of Nevada Inc. acquired a new stake in CG Oncology during the 4th quarter worth approximately $27,000. Comerica Bank raised its holdings in CG Oncology by 100.4% in the fourth quarter. Comerica Bank now owns 1,028 shares of the company’s stock valued at $43,000 after buying an additional 515 shares during the period. Fifth Third Bancorp purchased a new position in CG Oncology in the first quarter valued at approximately $74,000. Finally, KBC Group NV acquired a new position in CG Oncology during the first quarter valued at approximately $78,000. Hedge funds and other institutional investors own 26.56% of the company’s stock.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.